Developing antibodies to combat antibiotic-resistant bacterial infections
Multidimensional development of high-affinity anti-glycan antibodies to fight deadly bacterial infections
This study is working on new ways to help your immune system recognize and fight off tough bacteria by using special structures on their surface, which could lead to better vaccines and treatments for infections that don't respond to regular antibiotics.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Scripps Research Institute, the NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-11082422 on NIH RePORTER |
What this research studies
This research focuses on creating immunotherapies that target the surface structures of bacteria, known as glycans, which are crucial for their survival and virulence. By using advanced chemistry techniques, the research team will construct artificial platforms to display these glycans, making them recognizable to the immune system. The project aims to analyze immune responses to these glycans to develop effective vaccines and antibodies that can be used against antibiotic-resistant bacteria. The collaboration of experts in various fields will enhance the understanding of how to effectively combat these infections.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from severe bacterial infections, especially those caused by antibiotic-resistant strains.
Not a fit: Patients with infections caused by non-bacterial pathogens or those who do not respond to immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that effectively fight deadly bacterial infections, particularly those resistant to current antibiotics.
How similar studies have performed: Previous research has shown promising results in developing high-affinity antibodies against bacterial glycans, indicating potential for success in this novel approach.
Where this research is happening
La Jolla, United States
- Scripps Research Institute, the — La Jolla, United States (Active)
Researchers
- Principal investigator: Teyton, Luc — Scripps Research Institute, the
- Study coordinator: Teyton, Luc
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.